Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The neuropathic pain market

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Shifting composition for the neuropathic pain market.

References

  1. Datamonitor. Epidemiology: Peripheral Neuropathic pain — A common co-morbidity for HIV, diabetes, and herpes zoster. HC00221–001 (October 2011)

  2. Datamonitor. R&D Trends: Neuropathic pain — Extensive and diverse pipeline driven by high unmet need. HC00064–006 (July 2011).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sarah Nightingale.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nightingale, S. The neuropathic pain market. Nat Rev Drug Discov 11, 101–102 (2012). https://doi.org/10.1038/nrd3624

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3624

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing